-
Added ability to choose style type when modifying models. Currently supported styles are: "camel" for
variablesLikeThis
, "snake" forvariables_like_this
, "dot" forvariables.like.this
and "blank" forvariableslikethis
. This can be selected withsetCombineType()
. -
With the new combination style, you can change how
eta
variables are constructed with theoption(nlmixr2lib.etaCombineType="camel")
or whatever you wish it to the variable style to be. -
Added new model building framework for building models
-
PK model building functions
-
addTransit()
/removeTransit()
which were present before, but now modified and made a bit more robust, more closely matching literature method of transit compartments. -
addDepot()
/removeDepot()
which were present before, but modified to be a bit more robust. -
addWeibullAbs()
which adds a Weibull absorption to a PK model -
convertMM()
converts linear elimination to Michaelis-Menten elimination -
transPK()
converts thecl
style parameter transformations to various other PK transformations likek
,aob
,alpha
,k12
-
-
PD model building functions
-
addIndirectLin()
-- this adds an indirect effect model to a PK model that has a concentrationCc
in the model. This purposely uses a simple linear effect ofCc*Ek
orCc*Ik
so it will be easy to parse and turn into other functional forms (likeEmax
orHill
). If the PK model is not present it will useCc
as a covariate in a purely PD models. -
addIndirect()
-- this builds onaddIndirectLin()
and addsEmax
orHill
models to a PK model. You can also setimax=1
oremax=1
to drop these parameters from being estimated in the model. Additionallyhill=TRUE
will add a Hill coefficient to the sigmoid model. -
addEffectCmtLin()
-- this adds an effect compartment based on theCc
in the model. The linear effect can be modified into other function forms. -
addDirectLin()
-- this adds a direct effect model based on theCc
in the model. -
Changing functional forms of Effect models
-
convertEmax()
changes linear effect models to Emax models -
convertEmaxHill()
changes linear effect models to Hill models -
convertQuad()
changes linear effect models to quadratic models -
convertLogLin()
changes linear effect models to log-linear models
-
-
Changing functional forms of Baselines in non-indirect response models
-
addBaselineConst()
changes the zero baseline to a estimated constant -
addBaselineLin()
changes the zero baseline to a estimated constant and a linear constant with respect totime
. -
addBaselineExp()
changes the zero baseline to a exponential decay with respect to time -
addBaseline1exp()
-- the baseline effect is changed from zero to to an exponential approaching to a constant (with respect to time).
-
-
Changing model properties (all use
addCmtProp()
)-
addBioavailability()
adds bioavailability property to a compartment -
addRate()
adds a modeled rate to a compartment -
addDur()
adds modeled duration to a compartment -
addIni()
adds an initial value to a compartment -
addLag()
adds a lag time to the a compartment
-
-
-
Add Carlsson Petri (2021) liraglutide PK model
-
Add Cirincione (2017) exenatide immediate-release PK model
-
Add a variety of indirect response models
-
Add a variety of tumor growth inhibition models and move all oncology models into a new model database directory
-
Add a variety of double-absorption PK models
-
cp
and relatedcpddSd
andcppropSd
were renamed toCc
,CcAddSd
andCcPropSd
(fix #70). -
Multiple-endpoint models will have the
DV
column in the modeldb separated by commas.
- Work with the new
rxode2
version 2.0.12model()
andini()
assignment methods. - Therapeutic-area specific models have begun being added.
- Models can now give the user some additional information load via the
message
meta-data. - Models can now be in different directories. The change is for ease of maintaining the library, it is not a change that affects users.
- A regression where
addEta()
did not change the parameter, related to a change inrxode2
, was fixed. addEta()
detects where to add etas more robustly when covariates are on the parameter.
- Add Davda (2014) mAb consensus model
- Add Liu (2017) time-dependent clearance model based on nivolumab
- Add Kovalenko (2020) dupilumab PK model
- Add Soehoel (2022) tralokinumab PK model
- Add Zhu (2017) lebrikizumab PK model
- Initial version